PotBotics Takes Aim at the Vaporizer Market with RYAH
February 27th, 2019
News, Top News
Vaporizers have become ubiquitous across many parts of the country. You can’t walk more than ten minutes in Los Angeles or Denver without coming across someone vaping on the sidewalk. Not surprisingly, the market for vaporizers is projected to exceed $60 billion by 2025, creating a significant opportunity for investors. Tobacco and recreational cannabis have become hot areas of investment, but medical cannabis is ripe for innovation.
PotBotics Inc., a leading data aggregation and technology company in the global medical cannabis market, launched an innovative new vaporizer in December designed specifically for medical cannabis users. Investors may want to take a closer look at vaporizer trends and the company’s innovative approach as it looks to go public over the near-term.
CFN Media recently sat down with PotBotics Co-founder and CEO David Goldstein to demonstrate the company’s innovative new vaporizer product, RYAH
Growing Market for Vaporizers
The global e-cigarette and vaporizer market is projected to grow at a 20.8 percent compound annual growth rate to $61.4 billion by 2025, according to Research and Markets, which notes that the cannabis industry is a major source of growth in the industry. While the recreational cannabis industry represents a large potential market, vaporizers could be most impactful in the medical cannabis market where patients need alternatives to smoking.
Most medical users still smoke cannabis as their primary delivery method. After all, igniting buds is the simplest way to reach temperatures needed to release cannabinoids. The problem is that smoke inhalation delivers damaging carcinogens and other materials through the bronchial tree and into the lungs. Long-term exposure to these chemicals in the lungs can lead to a range of medical conditions, including COPD and lung cancer. Ignition methods can also be very inconsistent, which makes it hard to achieve predictable results.
Vaporizers are an increasingly popular alternative with fewer, if any, negative side-effects. Instead of burning buds and producing smoke, vaporizers dehydrate buds in a way that releases cannabinoids without ever catching fire. No carcinogens or other harmful chemicals ever enter the lungs, but users still benefit from the greater bioavailability of smoking versus other consumption methods that are subject to metabolism by the liver.
RYAH Ensures Predictable Results
Medical cannabis enjoys widespread support among doctors. In fact, a 2013 survey found that more than three-quarters of doctors would approve the use of medical marijuana. The problem is that there are few standardized delivery methods that guarantee dosages and measure the effects of cannabinoids in individual patients. In other words, it’s much harder for a doctor to tell a patient to go to a dispensary than for them to write a prescription.
PotBotics, a leading data aggregation and technology company in the global medical cannabis market, aims to change those dynamics with its new dose-measuring vaporizer. RYAH is the first vaporizer that lets users track and control a wide range of variables—including inhalation amount and temperatures—to ensure consistent and predictable results when used with its medical-grade oil or dry herb capsules.
RYAH Vaporizer and Companion App – Source: PotBotics Inc.
The company’s companion app lets consumers easily set their dosing parameters and track what medicine works best for them. In addition, the data can be shared with physicians and compiled into meaningful data sets to analyze efficacy. The company’s long-term goal is to advance the understanding of cannabinoids to a point where they can predict patient outcomes by measuring both individual experiences and medical literature.
“Consumers have picked up the micro-dosing trends, but unknowingly, have also accepted a lack of transparency for their medical regimen,” says PotBotics CEO David Goldstein. “RYAH is here to break that mold. We are very pleased to bring state-of-the-art technology to complement our existing suite of products in order to further understand and predict patient outcomes.”
PotBotics Inc. has developed an innovative vaporizer that cuts through the oversaturated market to help medical cannabis patients improve their experience. With the market projected to reach $60 billion by 2025, investors may want to take a closer look at the company as it rolls out RYAH, advances its data-driven products, and looks to go public over the near-term.
For more information, visit the company’s website at www.potbotics.com.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.